

해외 바이오의약품 임상 현황 (2020.07.13~2020.07.19)

한국바이오의약품협회, 2020.7.21.
출처: ClinicalTrials.gov

○ 미국 22건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04303117	NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma	Kaposi Sarcoma	Drug: NHS-IL12 Drug: M7824	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2
NCT04465760	Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis	Lymphoma Malignant Solid Neoplasm Plasma Cell Myeloma	Drug: Xisomab 3G3	OHSU Knight Cancer Institute National Heart, Lung, and Blood Institute (NHLBI) Oregon Health and Science University National Cancer Institute (NCI)	Phase 2
NCT04439825	Impact of Botox Treatment Into the Upper One Third of the Face (Glabella, Forehead Lines and/or Lateral Canthal Lines) an Area on Mood and Self -Appearance Satisfaction	Mood	Drug: Botulinum Neurotoxin Drug: Placebo	DeNova Research	Phase 1
NCT04432272	ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)	COVID-19 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infections	Biological: COVID-19 convalescent plasma	William Beaumont Hospitals	Phase 2
NCT04407442	Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab	Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma	Drug: Azacitidine Biological: Daratumumab Drug: Dexamethasone	University of California, San Francisco Janssen Pharmaceuticals	Phase 2
NCT04388852	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Aggressive Variant Prostate Carcinoma Castration-Resistant Prostate Carcinoma Metastatic Clear Cell Renal Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Prostate Carcinoma Metastatic Urothelial Carcinoma Stage IV Prostate Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8	Biological: Ipilimumab Drug: Valemetostat	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04323046	Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults	Glioblastoma Malignant Glioma Recurrent Glioblastoma Recurrent Malignant Glioma Recurrent Grade III Glioma Grade III Glioma	Biological: Ipilimumab Biological: Nivolumab Drug: Placebo Administration Other: Quality-of-Life Assessment Other: Questionnaire Administration	Sabine Mueller, MD, PhD Bristol-Myers Squibb Pacific Pediatric Neuro-Oncology Consortium University of California, San Francisco	Phase 1
NCT04318327	BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma	Multiple Myeloma	Biological: PHE885	Novartis Pharmaceuticals Novartis	Phase 1
NCT04242264	Phase 2 Shigella Vaccine and Challenge	Immunisation Shigella Infection	Other: Placebo Biological: Shigella sonnei strain 53G Biological: WRSs2	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
NCT04231877	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Aggressive Non-Hodgkin Lymphoma ALK-Positive Large B-Cell Lymphoma B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma, Not Otherwise Specified EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Primary Mediastinal (Thymic) Large B-Cell Lymphoma T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	Drug: Polatuzumab Vedotin Biological: Rituximab Drug: Prednisone Drug: Etoposide Drug: Doxorubicin Drug: Cyclophosphamide Biological: Filgrastim	University of Washington National Cancer Institute (NCI) Genentech, Inc.	Phase 1
NCT04231526	Pembrolizumab in Early Stage Colon Cancer	Colon Cancer	Drug: Pembrolizumab Procedure: Surgery	University of Chicago Merck Sharp & Dohme Corp.	Phase 2
NCT04219007	Vosoritide for Selected Genetic Causes of Short Stature	Short Stature	Drug: Vosoritide	Andrew Dauber Children's National Research Institute	Phase 2
NCT04208178	Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation	Advanced HER2+Breast Cancer	Drug: Alpelisib Drug: Alpelisib matching Placebo Drug: Trastuzumab Drug: Pertuzumab	Novartis Pharmaceuticals Novartis	Phase 3
NCT04174560	Phase I Norovirus Challenge Model	Gastroenteritis Norovirus	Biological: Norovirus GII.4 Challenge Pool	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04081337	A Study to Measure Food and Calorie Consumption in Very Overweight Participants Using Tirzepatide	Obesity	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04015700	Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma	Glioblastoma	Biological: Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics Device: CELLECTRA® 2000 EP Device supplied by Geneos Therapeutics Drug: Plasmid encoded IL-12	Washington University School of Medicine Inovio Pharmaceuticals	Phase 1
NCT03913117	Study of Treatment for HPV16+ ASC-US or LSIL	ASC-US LSIL	Biological: pNGVL4aCRTE6E7L2 Biological: TA-CIN	PapiVax Biotech, Inc. University of Alabama at Birmingham Johns Hopkins University	Phase 1
NCT04387071	CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	Locally Advanced Malignant Solid Neoplasm Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8 Unresectable Malignant Solid Neoplasm	Biological: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 Drug: VLP-encapsulated TLR9 Agonist CMP-001	University of Southern California National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04349267	Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors	Advanced Solid Tumor	Biological: BMS-986315 Biological: nivolumab Biological: cetuximab	Bristol-Myers Squibb	Phase 1 Phase 2
NCT04436276	A Study of Ad26COVS1 in Adults	Healthy	Biological: Ad26COVS1 Biological: Placebo	Janssen Vaccines & Prevention B.V.	Phase 1 Phase 2
NCT04476108	Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain	Diabetic Peripheral Neuropathic Pain	Drug: LY3016859 Drug: Placebo	Eli Lilly and Company	Phase 2
NCT04451408	A Study of LY3372993 in Participants With Alzheimer's Disease (AD)	Alzheimer Disease	Drug: LY3372993 Drug: Placebo	Eli Lilly and Company	Phase 1

해외 바이오의약품 임상 현황 (2020.07.13~2020.07.19)

한국바이오의약품협회, 2020.7.21.
출처: ClinicalTrials.gov

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04311424	Study of Tirzepatide in Healthy Participants	Healthy	Drug: 14C Tirzepatide	Eli Lilly and Company	Phase 1

○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04465695	Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19	COVID-19	Drug: Interferon beta-1b Drug: Clofazimine	The University of Hong Kong	Phase 2
NCT04335006	A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.	Breast Cancer Triple Negative Breast Cancer	Drug: Carelizumab Drug: Nab-paclitaxel Drug: Apatinib	Jiangsu HengRui Medicine Co., Ltd.	Phase 3
NCT04459078	Clinical Study of Camrelizumab Combined With Apatinib and Albumin Paclitaxel in Patients With Advanced Lung Adenocarcinoma	Adenocarcinoma of the Lung	Drug: Camrelizumab Drug: Albumin Paclitaxel Drug: Apatinib	Hunan Cancer Hospital Suzhou Sheng Diya Biomedical Co., Ltd.	Phase 2
NCT04308785	Atezolizumab Consolidation in Limited Stage Small Cell Lung Cancer	Carcinoma, Small Cell Lung	Drug: Atezolizumab Drug: Cisplatin Drug: Carboplatin Drug: Etoposide	Hoffmann-La Roche	Phase 2

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04475224	Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury	Acute Spinal Cord Injury	Drug: KP-100IT	Kringle Pharma, Inc.	Phase 3